Pharmacokinetics of convalescent plasma therapy in a COVID-19 patient with X-linked Agammaglobulinemia

Considerations on COVID-19 vaccination

“…Convalescent plasma has been authorized for emergency use by regulatory agencies in some countries as a treatment option for COVID-19, and consists in the transfusion of plasma from recovered (convalescent) COVID-19 patient(s) (as it contains antibodies against SARS-CoV-2) into a person who is actively infected with the virus. In the COVID-19 patient with X-linked agammaglobulinemia of the report, the administration of convalescent plasma did not associate with the presence of anti-SARS-CoV-2 antibodies, leading the authors to speculate that plasma dilution and/or accelerated antibody clearance could explain the variable efficacy of this approach in subjects treated with convalescent plasma [13] . It has to be noted, however, that different outcomes in recipients of convalescent plasma could as well be secondary to variability of antibody titers in different plasma preparations, and/or different viral epitopes targeted by the antibodies in different batches.…”

“…Another study evaluated the effects of passive immunization with convalescent plasma in a patient with a genetic deficiency in antibody production due to X-linked agammaglobulinemia [13] . Convalescent plasma has been authorized for emergency use by regulatory agencies in some countries as a treatment option for COVID-19, and consists in the transfusion of plasma from recovered (convalescent) COVID-19 patient(s) (as it contains antibodies against SARS-CoV-2) into a person who is actively infected with the virus.…”